Alteogen shares drop 14.7% after US drug price rule
KOSDAQ-listed biotech faces strategy limits as Washington tightens price-negotiation criteria for converted drugs.
KOSDAQ-listed biotech faces strategy limits as Washington tightens price-negotiation criteria for converted drugs. Published 2026-11-09 by Falling Shares.
| By Falling Shares Intelligence, edited by Wung Thomas, Editor-in-Chief
Written by Falling Shares Intelligence, our automated newsroom, from the public sources listed below and live market data. Every figure is checked against that material before publication, but the story has not been reviewed by a human editor. Check the linked sources before relying on it, and report errors to info@fallingshares.com.
Shares in Alteogen fell 14.72% on Monday after the U.S. government tightened price-negotiation criteria for drugs that convert, the company said in an exchange filing. The drop left the stock 60.2% below its 52-week high of 437,692.3 KRW.
US policy tightens drug pricing
Alteogen shares fell on the 9th after the U.S. government tightened price-negotiation criteria for drugs that convert, local media reported. The change affects the company’s SC switch strategy, which faces new limits under the revised rules.
None of the reports reviewed by Falling Shares gave a reason for the specific timing of the fall beyond the policy update. The company has not issued a separate statement detailing the financial impact of the change.
Stock trails market and peers
The decline came while the broader KOSDAQ index rose 0.1% in the same session. By Falling Shares' measure, almost all of the move was company-specific, with the market contributing just 0.1% to the total 14.7% drop.
Alteogen’s stock has lost 53.3% of its value over the past year. The current price of 171,000 KRW is 60.2% below the 52-week high of 437,692.3, and the stock is trading 37.5% below its 200-day average.